Newsroom

Sorted by: Latest
-

Circus Expands Trading Access to the U.S. Market via ADR Structure

MUNICH--(BUSINESS WIRE)--Circus SE (ISIN: DE000A2YN355 / XETRA: CA1), a global AI robotics company, today announced the establishment of a sponsored Level I American Depositary Receipt (ADR) program in the United States. Through this ADR structure, Circus shares can now be bought and traded by U.S. investors, settled locally, and held in U.S. brokerage accounts, while the company remains primarily listed on XETRA in Germany. “The sponsored ADR program supports our objective of expanding our int...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust IPOX Europe Equity Opportunities UCITS ETF 07.01.2026 IPXE.IM IE00BFD26097   75,002.00 EUR   1,758,583.86   23.447  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Cloud Computing UCITS ETF 07.01.2026 CPQ IE00BFD2H405 8,750,002.00 USD 482,206,169.18   55.109  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest US Equity Max Buffer UCITS ETF - December 07.01.2026 MDEC.LN IE0007FIJUO5 50,002.00 USD 1,373,408.88 27.467  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Dow Jones Internet UCITS ETF 07.01.2026 FDNU IE00BG0SSC32 2,325,002.00 USD  87,332,852.49   37.562  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Nasdaq Cybersecurity UCITS ETF 07.01.2026 NQCYBREN IE00BF16M727 28,228,879.00 USD 1,271,754,131.23   45.052  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Europe Growth Strength UCITS ETF 07.01.2026 FTEG.LN IE0009F7UB30 50,002.00 EUR 1,034,059.06 20.680  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust NYSE Arca Biotechnology UCITS ETF 07.01.2026 FBTU.LN IE00BL0L0H60  525,002.00 USD  14,081,673.06   26.822  ...
-

Riassunto: RoslinCT e BOOST Pharma annunciano la sottoscrizione di un accordo di produzione strategico per lo sviluppo di una terapia cellulare nei neonati affetti da osteogenesi imperfetta

EDIMBURGO, Scozia--(BUSINESS WIRE)--RoslinCT, un'organizzazione globale di sviluppo e produzione a contratto (CDMO) specializzata in terapie cellulari avanzate, e BOOST Pharma, un'azienda biotecnologica di fase clinica che si dedica allo sviluppo di terapie cellulari innovative per malattie scheletriche rare in età pediatrica, hanno annunciato oggi l'avvio di una partnership di produzione strategica a sostegno dello sviluppo della terapia cellulare di BOOST Pharma, BT-101, per il trattamento di...
-

Samenvatting: RoslinCT en BOOST Pharma maken een strategisch productieakkoord bekend om celtherapie voor baby's met osteogenesis imperfecta te bevorderen

EDINBURGH, Schotland--(BUSINESS WIRE)--RoslinCT, een internationale CDMO (Contract Development & Manufacturing Organization) gespecialiseerd in geavanceerde celtherapieën, en BOOST Pharma, een biotechnologiebedrijf in klinische fase die uitstekende celtherapieën voor zeldzame pediatrische skeletaandoeningen ontwikkelt, maakten vandaag een strategisch productieakkoord bekend om de ontwikkeling van BT-101, BOOST Pharma’s celtherapie voor de behandeling van baby's met OI (Osteogenesis Imperfec...